FDA Commissioner Scott Gottlieb said Wednesday (July 18) that the administration may be able to block the use of long-dated contracts between biologic makers and payors in Medicare Part B, which he argued “thwart competition by dangling big rebates to lock up payors in multi-year contracts right on the eve of biosimilar entry.” Gottlieb, who has not hesitated to opine on areas outside of his agency’s jurisdiction, called these contracts a “toxin.” Gottlieb, in a speech announcing his agency’s Biosimilar...